Racura fast-tracks RC220 cardioprotection data with novel blood test in CPACS trial

Race Oncology Ltd. ( (AU:RAC) ) has provided an update.

Racura Oncology has developed a new blood-based molecular test designed to measure how effectively its candidate RC220 protects the heart from damage caused by anthracycline chemotherapy, notably doxorubicin. Enabled by recent insights into the mechanism of (E,E)-bisantrene, the test will use patient samples from the ongoing RAC-010 cardioprotection and anticancer synergy trial to quantify RC220’s impact on cardiotoxic molecular pathways.

By integrating this assay into the early dose-escalation phase, Racura expects to obtain cardioprotective data more than two years ahead of prior plans, potentially accelerating clinical decision-making and improving trial safety and recruitment. Implementing the test required a modified trial protocol, including an initial doxorubicin-only cycle and extensive regulatory and ethics approvals across Australia, Hong Kong, and South Korea, with Australian clearance now in place and broader Asia approvals pending, as recruitment momentum begins to build again.

The most recent analyst rating on (AU:RAC) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on Race Oncology Ltd. stock, see the AU:RAC Stock Forecast page.

More about Race Oncology Ltd.

Racura Oncology Ltd is an Australia-based biotechnology company focused on developing novel oncology therapies, including the investigational cardioprotective and anticancer agent RC220 derived from (E,E)-bisantrene. The company targets patients receiving anthracycline-based chemotherapy, aiming to reduce cardiotoxic side effects while enhancing anticancer efficacy across key Asia-Pacific markets including Australia, Hong Kong, and South Korea.

Average Trading Volume: 213,353

Technical Sentiment Signal: Buy

Current Market Cap: A$408.4M

Find detailed analytics on RAC stock on TipRanks’ Stock Analysis page.